Natera Says New Data To Be Presented At 2023 ASCO Meeting In 13 Studies Across Multiple Cancer Types
Portfolio Pulse from Benzinga Newsdesk
Natera announced that new data will be presented at the 2023 ASCO Meeting in 13 studies across multiple cancer types, including oral presentations in Sarcoma and CRC, immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study, and updates from the CIRCULATE-Japan study in CRC.
May 30, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Natera's new data presentation at the 2023 ASCO Meeting in 13 studies across multiple cancer types may positively impact the company's stock price.
The presentation of new data at the 2023 ASCO Meeting demonstrates Natera's progress in cancer research and development. This may attract investors' attention and positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100